stockrow
Saturday 7 November 2026
Export IMCR’s income statement to Excel — free account
Immunocore Holdings PLC Sponsored ADR
IMCR Healthcare Biotechnology
Immunocore Holdings PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $400.0 million, up 29.0% from fiscal 2024.
- Revenue
- −1.42%
- EPS
- −7,900.0%
- Free cash flow
- +441.0%
- Total debt
- +0.55%
Quarter to September 2026, against a year earlier
30.90
2.50
+8.80%
Follow IMCR
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 6 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
4.37 | 3.71 | 3.76 | 3.64 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(53.51) | (111.09) | 101.61 | 77.74 | |
P/B ratio |
4.59 | 3.89 | 3.86 | 3.72 | |
Price to Tangible BV |
4.61 | 3.91 | 3.87 | 3.74 | |
EV/Sales |
3.31 | 2.73 | 2.74 | 2.57 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(123.66) | (45.23) | (33.77) | (105.97) | |
EV/FCF |
(88.01) | (36.66) | (28.69) | (60.61) | |
Quick Ratio |
3.80 | 3.86 | 4.15 | 4.31 | |
Current Ratio |
4.04 | 4.18 | 4.47 | 4.62 | |
Net Debt/EBITDA |
24.98 | (54.84) | 246.70 | 40.51 | |
Debt/Assets |
36.83% | 36.72% | 35.22% | 34.96% | |
Debt/Equity |
1.03 | 1.00 | 0.94 | 0.94 | |
Asset Turnover |
0.39 | 0.39 | 0.39 | 0.38 | |
Operating CF/Net income |
1.09 | (1.06) | (19.71) | (1.41) | |
Capex/Depreciation |
(3.45) | (1.88) | (0.77) | (2.12) | |
Interest Coverage |
(6.45) | 2.39 | (0.98) | (4.45) | |
Research and Development Expense of Revenue |
75.44% | 57.29% | 63.79% | 73.08% | |
Selling, General and Administrative Expense of Revenue |
40.82% | 35.48% | 37.86% | 39.57% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
7.98% | 5.91% | 8.11% | 9.52% | |
Graham Net Nets |
0.18 | 0.21 | 0.22 | 0.22 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(2.03%) | (1.80%) | (1.13%) | (2.10%) | |
Free Cash Flow Yield |
(0.86%) | (2.01%) | (2.54%) | (1.17%) | |
Revenue per Share |
2.08 | 2.10 | 2.27 | 1.98 | |
Operating CF per Share |
(0.65) | (0.27) | 0.31 | 0.39 | |
Capex per Share |
(0.06) | (0.04) | (0.02) | (0.05) | |
Free Cash Flow per Share |
(0.71) | (0.31) | 0.30 | 0.34 | |
Cash per Share |
17.16 | 16.65 | 17.27 | 17.48 | |
Shareholders Equity per Share |
7.57 | 7.76 | 8.24 | 8.14 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
7.57 | 7.76 | 8.24 | 8.14 | |
Free Cash Flow |
(35.53) | (15.56) | 15.14 | 17.74 | |
Working Capital |
750.05 | 763.69 | 815.85 | 830.81 | |
Capital Expenditures |
(2.88) | (1.78) | (0.79) | (2.35) | |
Net Current Asset Value |
310.51 | 325.39 | 351.42 | 350.90 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.02 | 0.01 | 0.02 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
68.49 | 72.08 | 82.56 | 81.96 | |
Average Payables |
24.73 | 29.63 | 25.09 | 22.17 | |
Average Inventory |
6.09 | 7.53 | 6.62 | 6.56 | |
Average Assets |
1,038.39 | 1,050.05 | 1,100.90 | 1,115.87 | |
Average Common Equity |
370.87 | 386.08 | 404.14 | 408.14 |
Columns are period end dates · fundamentals updated 6 Nov 2026